Navigation Links
Neurocrine Biosciences Reports Third Quarter 2011 Results
Date:10/31/2011

m the development program of elagolix for endometriosis were presented at the 2011 World Congress on Endometriosis this past September and during the 2011 Annual Meeting of the American Society for Reproductive Medicine earlier this month.

VMAT2 UpdateThe Company's VMAT2 inhibitor, NBI-98854, successfully completed two Phase I safety studies in healthy male volunteers and a Phase IIa study in tardive dyskinesia patients. Based on these three Canadian studies, the Company filed an Investigational New Drug Application with the FDA Division of Psychiatry Products.

Following the IND application with the FDA, a second Phase II study was initiated in the United States to further assess NBI-98854 in tardive dyskinesia patients. The design of this second Phase II study is a randomized, double-blind, placebo controlled, cross-over trial, using a within-subject comparison for safety and efficacy evaluation. This 32-patient study will assess once-daily NBI-98854 (12.5mg or 50mg) over a two-week dosing period. The primary endpoint of the study will be a comparison of placebo vs. active scores on the Abnormal Involuntary Movement Scale (AIMS). The study is currently enrolling subjects and the Company expects the results of this study in early 2012.

The Company is also conducting a three-month in-vivo toxicology study to support longer dosing regimens. This data is expected late in the fourth quarter of 2011. Pending the results of this toxicology study and the second Phase II study, a larger Phase IIb program is planned to be initiated in early 2012 to assess three-month dosing of NBI-98854.

Urocortin 2 UpdateThe Christchurch Cardioendocrine Research Group at University of Otago, Christchurch School of Medicine and Health Sciences, New Zealand, in collaboration with the Company, is enrolling patients with Acute Decompensated Heart Failure in a Phase II study of urocortin 2. The academic center expects the final enrollment to complete shortly.'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
5. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
6. Neurocrine Biosciences Reports Third Quarter 2008 Results
7. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
9. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
10. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
11. Neurocrine Announces Work Force Restructuring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 “Nature has developed, very ... that we desire in optical design,” said Joseph Shaw, ... University. “As we explore surfaces and structures at the ... were presented in San Diego in August during a ... Nature ” chaired by Shaw and Rongguang Liang of ...
(Date:9/16/2014)... phones to cars and flashlights, batteries play an ... companies constantly are seeking ways to improve battery ... using a water-based solution, researchers at the University ... efficient nuclear battery that could be used for ... in automobiles and also in complicated applications such ...
(Date:9/16/2014)... MA (PRWEB) September 16, 2014 CIRTEC ... of Brian Highley as CEO of CIRTEC. , ... exciting point for the Company.” noted Brian Highley. “The ... performance while sustaining strong organic growth over the past ... growth by continuing to improve and expand the services ...
(Date:9/16/2014)...  LABSCO, the leading specialty sales agent of ... office laboratories and alternate healthcare settings is proud ... will serve as Siemens Healthcare Diagnostics, exclusive sales ... a semi-exclusive sales distributor in specified POL market ... States . LABSCO will be responsible for ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3
... engine dedicated to recruiting exceptional talent to jobs at ... the most rewarding careers on the planet, but they ... StartUpHire website, www.startuphire.com , lists thousands of jobs ... investor, and more. Search agents allow users to ...
... (Pink Sheets: SYNJ), Reports that it has engaged in ... The job of the Director will be to coordinate ... Pinnacle Energy Division. The Company is currently considering ventures ... production, and microwave plasma physics. To that end, the ...
... NOVATO, Calif., March 18 BioMarin Pharmaceutical Inc. (Nasdaq: ... for clinical trial authorization (CTA) for BMN 110 or ... lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or ... Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). BioMarin ...
Cached Biology Technology:StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies 2StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies 3Syndication Inc. Seeks 'DIRECTOR OF TECHNICAL ENGINEERING' for 'PINNACLE ENERGY' - Its New Alternative Energy Subsidiary 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 3BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 4
(Date:9/16/2014)... such as buying clothing not made in a sweat ... their own bags when they go shopping? According to ... Research , ethical consumption is motivated by a need ... into action. , "Advocates of ethical consumerism suggest that ... the products they choose, but unfortunately only a small ...
(Date:9/16/2014)... Sept. 16, 2014  Cross Match Technologies, a ... announced today the launch of its Verifier ® ... identity of an individual using their secure credentials ... rapidly reads credential documents with embedded biometric data ... the biometric to a live scan of their ...
(Date:9/15/2014)... (September 15, 2014) The so-called central dogma ... proteinhas long provided a simplified explanation for how ... organisms. , In reality, of course, the ... first articulated nearly 60 years ago by Nobel ... structure. For one, there are multiple types of ...
Breaking Biology News(10 mins):Why are consumers willing to spend more money on ethical products? 2Cross Match Launches New Identity Management Handheld Solution 2Scientists discover RNA modifications in some unexpected places 2
... discovery by UNC scientists describes how cells infected by ... called exosomes, changing their cellular "cargo" of proteins and ... the growth of recipient cells from benign to cancer-producing. ... effects and potentially manipulate other cells throughout the body. ...
... University of California, San Diego School of Medicine and ... approved drugs to more than 1,000 proteins in Mycobacterium ... avenues to repurpose these drugs to treat TB. ... Computational Biology . "Tuberculosis is currently one of ...
... study by researchers at the Johns Hopkins Bloomberg School of ... disease among male clients of the commercial sex industry in ... drug use as the primary transmission mode of all HIV ... of publication in the journal Sexually Transmitted Infections . ...
Cached Biology News:UNC scientists identify cellular communicators for cancer virus 2TB-drugome provides new targets for anti-tuberculosis drug discovery 2Study examines risk of heterosexual HIV transmission in China 2